Wednesday, February 24, 2021 5:06:09 PM
This one does really goo job highlighting 2021 BUsiness Outlook. Breaks down what is coming up this year.
https://www.globenewswire.com/news-release/2021/02/10/2172785/0/en/ObsEva-Provides-Business-Outlook-for-2021.html
Breaks down Linzagolix ( Yselty UF) trials and what it actually does.
https://endometriosisnews.com/obe2109/
This one talks about competitors and possible safety issues.
https://www.evaluate.com/vantage/articles/news/trial-results/obseva-shows-why-red-flags-are-worth-heeding
The actual clinical trials data https://clinicaltrials.gov/ct2/show/NCT03992846
SOme of the peer reviewed and cited articles related to linzagolix
https://pubmed.ncbi.nlm.nih.gov/32505383/
https://pubmed.ncbi.nlm.nih.gov/32100275/
https://journals.lww.com/greenjournal/Abstract/2020/05001/Linzagolix_for_Endometriosis_Associated_Pain_.82.aspx
https://www.fertstert.org/article/S0015-0282(19)31540-7/abstract
MOst recent as of 02/21 FDA approval info- need to further investigate what else I can find here ( focus) https://www.clinicaltrialsarena.com/comment/loa-obseva-yselty-endometriosis/
Info on market size of endometriosis
https://www.marketwatch.com/press-release/endometriosis-treatment-market-to-grow-15x-by-2030-2021-02-19#:~:text=Rising%20prevalence%20of%20gynecological%20disorders,US%24%204%20Bn%20by%202030.
https://www.futurewiseresearch.com/healthcare-market-research/Endometriosis-Treatment-Market/8911
Recent OBSV News
- ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin • GlobeNewswire Inc. • 04/03/2024 05:00:00 AM
- ObsEva Announces Update on Board of Directors • GlobeNewswire Inc. • 03/19/2024 06:00:00 AM
- ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023 • GlobeNewswire Inc. • 02/28/2024 06:00:00 AM
- Geneva Court Grants Temporary Moratorium to ObsEva • GlobeNewswire Inc. • 01/31/2024 06:00:00 AM
- ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals • GlobeNewswire Inc. • 11/30/2023 06:00:00 AM
- Organon Returns Ebopiprant to XOMA • GlobeNewswire Inc. • 10/27/2023 09:00:00 PM
- ObsEva Files half Year 2023 Financial Statements • GlobeNewswire Inc. • 09/27/2023 05:00:00 AM
- ObsEva Recovers Full Worldwide Rights on Nolasiban • GlobeNewswire Inc. • 07/13/2023 05:00:00 AM
- Annual General Meeting 2023 • GlobeNewswire Inc. • 06/08/2023 05:00:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM